Chronic pain from damage to the nervous system is extremely debilitating and notoriously difficult to treat. The current drug of choice, gabapentin, has serious side effects and only works in two-thirds of patients. We have developed a drug, derived from sea snail venom, that exhibits ten times the activity of gabapentin. This proposal seeks to progress our drug to clinical trials and attract a commercial partner for its development into the market.
Development Of The Listening In Spatialized Noise - Tonal Test (or LiSN-T)
Funder
National Health and Medical Research Council
Funding Amount
$227,136.00
Summary
In this project a novel listening test software will be developed for diagnosing spatial processing disorder in children. These children often have difficulties in understanding teachers in classrooms, which can significantly impact their ability to learn. The developed software will be specifically designed for diagnosing 5-year old children, before they enter primary school, and in contrast to existing tests will be independent of their language background.
Pain is a debilitating condition that affects the life of one in five Australians and has significant socioeconomic impact. Currently available pain killers often do not work, or have intolerable side effects including sedation and addiction. We have discovered a novel compound that avoids these side effects and provides effective analgesia as well as opioid-sparing effects in a number of relevant animal models. The aim of this project is to progress the compound towards clinical development.